Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The incidence of both type 1 and type 2 diabetes is increasing worldwide. Diabetic peripheral neuropathy (DPN) is among the most distressing and costly of all the chronic complications of diabetes and is a cause of significant disability and poor quality of life. This incurs a significant burden on health care costs and society, especially as these young people enter their peak working and earning capacity at the time when diabetes-related complications most often first occur. DPN is often asymptomatic during the early stages; however, once symptoms and overt deficits have developed, it cannot be reversed. Therefore, early diagnosis and timely intervention are essential to prevent the development and progression of diabetic neuropathy. The diagnosis of DPN, the determination of the global prevalence, and incidence rates of DPN remain challenging. The opinions vary about the effectiveness of the expansion of screenings to enable early diagnosis and treatment initiation before disease onset and progression. Although research has evolved over the years, DPN still represents an enormous burden for clinicians and health systems worldwide due to its difficult diagnosis, high costs related to treatment, and the multidisciplinary approach required for effective management. Therefore, there is an unmet need for reliable surrogate biomarkers to monitor the onset and progression of early neuropathic changes in DPN and facilitate drug discovery. In this review paper, the aim was to assess the currently available tests for DPN’s sensitivity and performance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hawker, G. A., Mian, S., Kendzerska, T., & French, M. (2011) · Arthritis Care & Research · doi:10.1002/acr.20543 · Cited by 4,924
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“The ‘ Action to Control Cardiovascular Risk in Diabetes ’ (ACCORD) (20) trial and the ‘ Veteran Affairs Diabetes Trial ’ (21) found that DPN was present in 42% and 39% of adults with type 2 diabetes, respectively, at baseline measurement.”
BackgroundThe short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690 · cited 3×
“In 2010, the Toronto Consensus, by an expert panel recommended that one abnormal fi nding as part of NCS, combined with a symptom or sign of neuropathy should be used to con fi rm DPN (41).”
BackgroundDiabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 5×
“Patients may also suffer from sudomotor dysfunction, hypoglycemia obliviousness, and abnormal pupillary function (5).”
BackgroundInfluentialFeldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Young, M. J., Boulton, A. J. M., Macleod, A. F., Williams, D. R. R., & Sonksen, P. H. (1993) · Diabetologia · doi:10.1007/bf00400697 · Cited by 1,502
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 3×
“The ‘ Action to Control Cardiovascular Risk in Diabetes ’ (ACCORD) (20) trial and the ‘ Veteran Affairs Diabetes Trial ’ (21) found that DPN was present in 42% and 39% of adults with type 2 diabetes, respectively, at baseline measurement.”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323 · cited 4×
“The prevalence of diabetic peripheral neuropathy (DPN) reported in various studies ranges from 6% to 51% depending on the population (15, 16).”
BackgroundInfluentialTesfaye, S., Stevens, L. K., Stephenson, J. M., Fuller, J. H., Plater, M., Ionescu-Tirgoviste, C., Nuber, A., Pozza, G., & Ward, J. D. (1996) · Diabetologia · doi:10.1007/s001250050586 · Cited by 695 · cited 1×
“In a cohort of patients with T1DM, the EURODIAB prospective complications (25) study reported similar modi fi able risk factors to those identi fi ed in T2DM, explicitly having an association with raised triglyceride level, obesity, smoking and hypertension.”
BackgroundLifestyle intervention for pre-diabetic neuropathy
Smith, A. G., Russell, J., Feldman, E. L., Goldstein, J., Peltier, A., Smith, S., Hamwi, J., Pollari, D., Bixby, B., Howard, J., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0224 · Cited by 585
Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study
Lauria, G., Bakkers, M., Schmitz, C., Lombardi, R., Penza, P., Devigili, G., Smith, A. G., Hsieh, S., Mellgren, S. I., Umapathi, T., et al. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00271.x · Cited by 518 · cited 2×
“At present, age-related normative values exist only for BFI, published by a multi-national group of 8 centers (115).”
BackgroundInfluentialMartin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2114 · Cited by 499 · cited 2×
“The Epidemiology of Diabetes Interventions and Complications (EDIC) trial reported that intensive glucose control signi fi cantly delayed the development and progression of diabetic neuropathy in T1DM patients over time (17).”
BackgroundValidation of the Toronto Clinical Scoring System for diabetic polyneuropathy
Bril, V., & Perkins, B. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2048 · Cited by 472 · cited 2×
“The maximum score is 19, and the test is able to stratify patients into no DPN, mild DPN, moderate DPN and severe DPN depending on the overall score (92).”
BackgroundMethod11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Kluding, P. M., Pasnoor, M., Singh, R., Jernigan, S., Farmer, K., Rucker, J., Sharma, N. K., & Wright, D. E. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.05.007 · Cited by 370 · cited 1×
“Several studies have demonstrated a potential for improved outcomes in patients with diagnosed DPN through exercise regimes put in place over ten weeks (33) to 12 months (34).”
BackgroundSweat testing to evaluate autonomic function
Illigens, B. M. W., & Gibbons, C. H. (2009) · Clinical Autonomic Research · doi:10.1007/s10286-008-0506-8 · Cited by 255 · cited 1×
“software is used to digitalise, plot and analyze the temporal resolution, latency, magnitude and duration of the sudomotor response (123).”
MethodAndersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2062 · Cited by 248 · cited 1×
“In cohorts of patients with T2DM, several metabolic syndromes such as hypertension, abdominal obesity, lower high-density lipoprotein (HDL) levels and hypertriglyceridemia have been consistently associated with DPN development (23), with additional independent risk factors including alcohol abuse and increased height…”
BackgroundTavakoli, M., Ferdousi, M., Petropoulos, I. N., Morris, J., Pritchard, N., Zhivov, A., Ziegler, D., Pacaud, D., Romanchuk, K., Perkins, B. A., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2311 · Cited by 222 · cited 1×
“This is likely due to their signi fi cantly older-aged cohort compared to the other cross-sectional studies as CNFD and CNFL have been shown to reduce with age (188).”
ResultSelf-citationCardoso, C. R. L., Leite, N. C., Moram, C. B. M., & Salles, G. F. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0677-0 · Cited by 222 · cited 1×
“In the follow-up study of T2DM (a median of 9.3 years), mean HbA1c levels were the main risk predictor for the composite outcome of developing or worsening diabetic neuropathy, whereas glycemic variability assessed by HbA1c variability was a better risk predictor for new incident of neuropathy (36).”
BackgroundInfluentialInfluence of aging on thermal and vibratory thresholds of quantitative sensory testing
Lin, Y., Hsieh, S., Chao, C., Chang, Y., & Hsieh, S. (2005) · Journal of the Peripheral Nervous System · doi:10.1111/j.1085-9489.2005.10305.x · Cited by 176 · cited 4×
“Training of both examiner and patient, the methodology of assessment, baseline skin temperature, stimulus characteristics, location and number of stimuli sites and duration of intervals between tests have all affected QST measurements (52).”
BackgroundMethodInfluentialAzmi, S., Ferdousi, M., Petropoulos, I. N., Ponirakis, G., Alam, U., Fadavi, H., Asghar, O., Marshall, A., Atkinson, A. J., Jones, W., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2733 · Cited by 148
Self-citationClinical neuropathy scales in neuropathy associated with impaired glucose tolerance
Zilliox, L. A., Ruby, S. K., Singh, S., Zhan, M., & Russell, J. W. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.01.011 · Cited by 85
Cited by
Sakane, N., Kato, K., Hata, S., Nishimura, E., Araki, R., kouyama, K., Hatao, M., Matoba, Y., Matsushita, Y., Domichi, M., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01024-x · Cited by 10
Metadata
- Authors
- Carmichael, J., Fadavi, H., Ishibashi, F., Shore, A. C., & Tavakoli, M.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2021-05-26
- Volume
- 12
- Pages
- 671257-671257
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3165517566
- Cited by
- 176
- References
- 24
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.